Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma

By sjmartinez • March 20, 2025

Dummer R, Sandhu S, Miller WH, Butler MO, Taylor MH, Heinzerling L, Blank CU, Munoz-Couselo E, Burris HA, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich AH, Mauch C, Kleha JF, Polli A, Harney AS, di Pietro A, Ascierto PA. Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma. Clin Cancer Res. 2025 Mar 19. doi: 10.1158/1078-0432.CCR-24-0254. Epub ahead of print. PMID: 40106536.

Tags: Hematology/Oncology, Publications

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin[...]

Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial

Harbeck N, Dieras V, Gelmon KA, Finn RS, Martin M, Neven P, Kim S, Ma J, Gauthier E, Broughton E, Doan J, Rugo HS. Effect[...]

Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801)

Othus M, Sharon E, Wu MC, Sondak VK, Ribas A, Patel SP. Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor[...]